Home › Parkinson's Disease › NCT06234995
Cortical Electrophysiology of Response Inhibition in Parkinson's Disease
Who can join
Ages 45 to 75 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria for Persons with Parkinson's Disease for Aim 1: * diagnosis of idiopathic Parkinson's disease (PD) * Hoehn and Yahr (H\&Y) stage 2-4 (off medication) Exclusion Criteria for Persons with Parkinson's Disease for Aim 1: * severe tremor at rest or severe dyskinesia which would cause significant artifacts in electrophysiological signals * inability to hold antiparkinsonian medications for research recordings * dementia * non-English speaker Inclusion Criteria for Persons with Parkinson's Disease for Aim 2: * diagnosis of idiopathic PD * there is a clinical indication for DBS surgery * normal preoperative MRI * ability to tolerate microelectrode-guided neurosurgery in an awake state Exclusion Criteria for Persons with Parkinson's Disease for Aim 2: * presence of a coagulopathy * uncontrolled hypertension * heart disease * other medical conditions considered to increase the patient's risk for surgical complications Inclusion Criteria for Persons with Parkinson's Disease for Aim 3: * diagnosis of idiopathic PD * functioning DBS system Exclusion Criteria for Persons with Parkinson's Disease for Aim 3: * severe tremor at rest or severe dyskinesia which would cause significant artifacts in electrophysiological signals * inability to hold antiparkinsonian medications for research recordings * inability to tolerate temporary discontinuation of DBS therapy or alteration of stimulation settings for research purposes * other medical conditions considered to increase the patient's risk for surgical complications Inclusion Criteria for Healthy Controls: * age 45-75 Exclusion Criteria for Healthy Controls: * history of a neuropsychiatric disorder and/or treatment with psychotropic medications * non-English speaker
About the study
Patients with Parkinson's Disease will be studied before, during, and after a deep brain stimulation implantation procedure to see if the stimulation location and the size of the electrical field produced by subthalamic nucleus (STN) DBS determine the degree to which DBS engages circuits that involve prefrontal cortex executive functions, and therefore have a direct impact on the patient's ability to inhibit actions.
What is being tested
- Levodopa (drug)
- Clinical DBS Setting (device)
- Sham DBS (device)
- DBS Setting Maximizing Prefrontal Activation (device)
- DBS Setting Minimizing Prefrontal Activation (device)
Sponsor: Emory University · Participants: 80 · Started: Aug 9, 2021
Contact the study team
- Jonna Seppa · Phone: 404-727-1509
- Svjetlana Miocinovic, MD, PhD · Phone: 404-712-9065
Official record on ClinicalTrials.gov — NCT06234995
Locations in the U.S.
| Georgia | Emory Brain Health Center, Atlanta Emory University Hospital, Atlanta |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.